Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Solid Cancers

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 51, pages 1082–1086 (2016)Cite this article

Subjects

A Corrigendum to this article was published on 16 January 2017

Abstract

Breast cancer carrying BRCA mutation may be highly sensitive to DNA-damaging agents. We hypothesized a better outcome for BRCA-mutated (BRCAmut) metastatic breast cancer (MBC) patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDC AHSCT) versus unaffected BRCA (BRCA wild type; (BRCAwt)) or patients without documented BRCA mutation (BRCA untested (BRCAut)). All female patients treated for MBC with AHSCT at Institut Paoli-Calmettes between 2003 and 2012 were included. BRCAmut and BRCAwt patients were identified from our institutional genetic database. Overall survival (OS) was the primary end point. A total of 235 patients were included. In all, 15 patients were BRCAmut, 62 BRCAwt and 149 BRCAut. In multivariate analyses, the BRCAmut status was an independent prognostic factor for OS (hazard ratio (HR): 3.08, 95% confidence interval (CI): 1.10–8.64, P=0.0326) and PFS (HR: 2.52, 95% CI :1.29–4.91, P=0.0069). In this large series of MBC receiving HDC AHSCT, we report a highly favorable survival outcome in the subset of patients with documented germline BRCA mutations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–1130.

    Article  CAS  Google Scholar 

  2. King M-C, Marks JH, Mandell JB,, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643–646.

    Article  CAS  Google Scholar 

  3. Moynahan ME, Chiu JW, Koller BH, Jasin M . Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4: 511–518.

    Article  CAS  Google Scholar 

  4. Moynahan ME, Pierce AJ, Jasin M . BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263–272.

    Article  CAS  Google Scholar 

  5. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011; 29: 3214–3223.

    Article  CAS  Google Scholar 

  6. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 2011; 29: 3224–3231.

    Article  Google Scholar 

  7. Martino M, Lanza F, Pavesi L, Öztürk M, Blaise D, Núñez RL et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in high-risk breast cancer: data from the European Group for Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2015; 22: 475–481.

    Article  Google Scholar 

  8. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50: 1037–1056.

    Article  CAS  Google Scholar 

  9. Pedrazzoli P, Martinelli G, Gianni AM, Da Prada GA, Ballestrero A, Rosti G et al. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. Biol Blood Marrow Transplant 2014; 20: 501–506.

    Article  CAS  Google Scholar 

  10. Huszno J, Budryk M, Kołosza Z, Nowara E . The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 2013; 85: 278–282.

    Article  CAS  Google Scholar 

  11. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP . The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659–1668.

    Article  CAS  Google Scholar 

  12. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L . Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229.

    Article  CAS  Google Scholar 

  13. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MBE, Bartels CCM et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 3764–3771.

    Article  Google Scholar 

  14. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK et al. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 2013; 30: 631–642.

    Article  CAS  Google Scholar 

  15. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CHM et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012; 118: 899–907.

    Article  CAS  Google Scholar 

  16. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902–1909.

    Article  CAS  Google Scholar 

  17. Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Gonçalves A, Campone M et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol 2014; 25: 1152–1158.

    Article  CAS  Google Scholar 

  18. Martino M, Bottini A, Rosti G, Generali D, Secondino S, Barni S et al. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opin Biol Ther 2012; 12: 1505–1515.

    Article  CAS  Google Scholar 

  19. Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342: 1069–1076.

    Article  CAS  Google Scholar 

  20. Martino M, Ballestrero A, Zambelli A, Secondino S, Aieta M, Bengala C et al. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplant 2013; 48: 414–418.

    Article  CAS  Google Scholar 

  21. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 2005; 23: 432–440.

    Article  CAS  Google Scholar 

  22. Lotz J-P, Curé H, Janvier M, Asselain B, Morvan F, Legros M et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 2005; 41: 71–80.

    Article  CAS  Google Scholar 

  23. Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 2006; 12: 195–203.

    Article  CAS  Google Scholar 

  24. Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant 2008; 41: 555–562.

    Article  CAS  Google Scholar 

  25. Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 2008; 26: 37–43.

    Article  CAS  Google Scholar 

  26. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005; 366: 1935–1944.

    Article  CAS  Google Scholar 

  27. Rodenhuis S, Bontenbal M, van Hoesel QGCM, Smit WM, Nooij MA, Voest EE et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006; 17: 588–596.

    Article  CAS  Google Scholar 

  28. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225–233.

    Article  CAS  Google Scholar 

  29. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515–521.

    Article  CAS  Google Scholar 

  30. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17–26.

    Article  CAS  Google Scholar 

  31. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005; 23: 2191–2200.

    Article  Google Scholar 

  32. Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004; 22: 2273–2283.

    Article  CAS  Google Scholar 

  33. Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C, Bengala C et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 2005; 16: 726–734.

    Article  CAS  Google Scholar 

  34. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384–1391.

    Article  CAS  Google Scholar 

  35. Roche H, Viens P, Biron P, Lotz J-P, Asselain B PEGASE Group. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 2003; 10: 42–47.

    Article  Google Scholar 

  36. Leonard RCF, Lind M, Twelves C, Coleman R, van Belle S, Wilson C et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 2004; 96: 1076–1083.

    Article  CAS  Google Scholar 

  37. International Breast Cancer Study Group, Basser RL, O’Neill A, Martinelli G, Green MD, Peccatori F et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006; 24: 370–378.

    Article  Google Scholar 

  38. Moore HCF, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol 2007; 25: 1677–1682.

    Article  CAS  Google Scholar 

  39. Turner N, Tutt A, Ashworth A . Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer 2004; 4: 814–819.

    Article  CAS  Google Scholar 

  40. Muggia F, Safra T . “BRCAness” and its implications for platinum action in gynecologic cancer. Anticancer Res 2014; 34: 551–556.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011; 22: 1561–1570.

    Article  CAS  Google Scholar 

  42. Schouten PC, Marmé F, Aulmann S, Sinn H-P, van Essen HF, Ylstra B et al. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. Clin Cancer Res 2015; 21: 763–770.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by SIRIC program (INCa-DGOS-Inserm 6038).

Author information

Author notes

  1. L Boudin and A Gonçalves: These authors contributed equally to this work.

Authors and Affiliations

  1. Département d’Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France

    L Boudin, A Gonçalves, R Sabatier, F Bertucci, J-M Extra, C Tarpin & P Viens

  2. Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France

    A Gonçalves, R Sabatier, F Bertucci, G Houvenaegel, E Lambaudie, E Charafe-Jauffret, B Calmels, P Viens, F Eisinger & C Chabannon

  3. Aix-Marseille Université, Marseille, France

    A Gonçalves, F Bertucci, G Houvenaegel, E Lambaudie, H Sobol, E Charafe-Jauffret, P Viens, F Eisinger & C Chabannon

  4. Département d'Anticipation et de Suivi du Cancer, Institut Paoli-Calmettes, Marseille, France

    J Moretta, P Asseeva, D Livon, H Sobol & F Eisinger

  5. Département de la Recherche Clinique et de l’Innovation (DRCI), Biostatistiques, Institut Paoli-Calmettes, Marseille, France

    P Sfumato & J-M Boher

  6. Département de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France

    G Houvenaegel & E Lambaudie

  7. Département de Radiothérapie, Institut Paoli-Calmettes, Marseille, France

    A Tallet & M Resbeut

  8. Département de Biologie du Cancer Institut Paoli-Calmettes, Biopathologie, Marseille, France

    E Charafe-Jauffret & C Chabannon

  9. Département de Biologie du Cancer, Centre de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France

    B Calmels, C Lemarie & C Chabannon

  10. Centre d’Investigations Cliniques en Biothérapies, Marseille, France

    B Calmels & C Lemarie

Authors
  1. L Boudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Sabatier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Moretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Sfumato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Asseeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Livon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Bertucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J-M Extra
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Tarpin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G Houvenaegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Lambaudie
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Tallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Resbeut
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H Sobol
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. E Charafe-Jauffret
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. B Calmels
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. C Lemarie
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. J-M Boher
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. P Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. F Eisinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Chabannon.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

This work was presented in part at the 2015 EBMT Annual Meeting held in Istanbul, Turkey, 22–25 March 2015.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boudin, L., Gonçalves, A., Sabatier, R. et al. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 51, 1082–1086 (2016). https://doi.org/10.1038/bmt.2016.82

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.82

This article is cited by

Search

Advanced search

Quick links